{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.25","value":"0.3"},{"groupId":"OG001","spread":"1.14","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"417"},{"groupId":"OG001","value":"414"}],"units":"Participants"}],"title":"NSLV, Cycle 1 (n=417,414)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"0.3"},{"groupId":"OG001","spread":"1.35","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"363"}],"units":"Participants"}],"title":"NSLV, Cycle 2 (n=345,363)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.67","value":"0.2"},{"groupId":"OG001","spread":"0.58","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"title":"NSLV, Cycle 3 (n=299,304)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.49","value":"0.1"},{"groupId":"OG001","spread":"0.47","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"NSLV, Cycle 4 (n=265,254)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.44","value":"0.1"},{"groupId":"OG001","spread":"0.56","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"414"}],"units":"Participants"}],"title":"NSRV, Cycle 1 (n=419,414)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.36","value":"0.1"},{"groupId":"OG001","spread":"0.88","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"364"}],"units":"Participants"}],"title":"NSRV, Cycle 2 (n=348,364)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.28","value":"0.0"},{"groupId":"OG001","spread":"0.33","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"title":"NSRV, Cycle 3 (n=299,305)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"0.0"},{"groupId":"OG001","spread":"0.46","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"NSRV, Cycle 4 (n=266,255)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.44","value":"0.0"},{"groupId":"OG001","spread":"0.77","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"418"},{"groupId":"OG001","value":"411"}],"units":"Participants"}],"title":"HHV, Cycle 1 (n=418,411)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.52","value":"0.1"},{"groupId":"OG001","spread":"0.64","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"343"},{"groupId":"OG001","value":"363"}],"units":"Participants"}],"title":"HHV, Cycle 2 (n=343,363)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.72","value":"0.1"},{"groupId":"OG001","spread":"0.37","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"title":"HHV, Cycle 3 (n=298,304)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.49","value":"0.0"},{"groupId":"OG001","spread":"1.77","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"HHV, Cycle 4 (n=265,254)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.69","value":"0.2"},{"groupId":"OG001","spread":"2.52","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"417"},{"groupId":"OG001","value":"413"}],"units":"Participants"}],"title":"NSP, Cycle 1 (n=417,413)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"0.2"},{"groupId":"OG001","spread":"1.17","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"363"}],"units":"Participants"}],"title":"NSP, Cycle 2 (n=344,363)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.60","value":"0.2"},{"groupId":"OG001","spread":"1.98","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"title":"NSP, Cycle 3 (n=298,304)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.85","value":"0.2"},{"groupId":"OG001","spread":"1.73","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"NSP, Cycle 4 (n=266,254)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"The number of non-study laboratory visits (NSLVs), non-study radiology visits (NSRVs), and home healthcare visits (HHVs) were each collected as a single question on the eCRF. The number of non-study medical or surgical procedures (MSPs) was defined as the sum of procedures performed at outpatient or physician clinics, as well as those performed during any inpatient hospitalization.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Only those participants who had NSLVs, NSRVs, HHVs, and medical procedures were analyzed.","reportingStatus":"POSTED","timeFrame":"Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Mean Number of Laboratory Visits, Radiology Visits, Home Healthcare Visits, and Medical Procedures at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"visits"}